TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Stock
Certificat
DE000SF7VV31
| Delayed Deutsche Boerse AG 07:33:11 2024-05-23 am EDT | ||
| 21.28 EUR | -0.84% |
|
| Current month | +26.01% | ||
| 1 month | +20.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 21.28 | -0.84% |
| 24-05-22 | 21.46 | +2.83% |
| 24-05-21 | 20.87 | -2.75% |
| 24-05-20 | 21.46 | +1.04% |
| 24-05-17 | 21.24 | +2.12% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 07:33 am EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7VV3 |
| ISIN | DE000SF7VV31 |
| Date issued | 2021-08-18 |
| Strike | 216.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.96 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.04 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.27 € |
| Spread % | 1.24% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
447.5
USD
Average target price
462.8
USD
Spread / Average Target
+3.41%
- Stock Market
- Certificates
- Certificat
